{"entity":{"id":"mrt-2359","kind":"drug","name":"MRT-2359","aka":[],"tldr":"MRT-2359 is an experimental oral molecular glue degrader from Monte Rosa Therapeutics, in phase 2 trials for castration-resistant prostate cancer.","summary":"MRT-2359 is an oral molecular glue degrader from Monte Rosa Therapeutics. An orally bioavailable molecular glue degrader of the translation termination factor GSPT1; by disrupting translation it reduced levels of prostate cancer oncoproteins including androgen receptor, MYC and cyclin D1 in preclinical models. Its furthest stage is phase 2, for castration-resistant prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Pipeline graphic shows 'Phase 1' but the same page describes the ongoing phase 2 MODeFIRe-1 study (NCT07745361, registry phase 2, recruiting) with apalutamide. Earlier phase 1/2 NCT05546268 is active, not recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Monte Rosa Therapeutics: monterosatx.com","url":"https://www.monterosatx.com/pipeline/"},{"label":"Monte Rosa Therapeutics: monterosatx.com","url":"https://www.monterosatx.com/pipeline/"},{"label":"Monte Rosa Therapeutics: monterosatx.com","url":"https://www.monterosatx.com/pipeline/"},{"label":"Monte Rosa Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07745361"},{"label":"ClinicalTrials.gov: trials of MRT-2359","url":"https://clinicaltrials.gov/search?intr=MRT-2359"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["monte-rosa"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07745361","nct05546268"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MRT-2359","modality":"Oral molecular glue degrader","mechanism":"An orally bioavailable molecular glue degrader of the translation termination factor GSPT1; by disrupting translation it reduced levels of prostate cancer oncoproteins including androgen receptor, MYC and cyclin D1 in preclinical models.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mrt-2359/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"company":[{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/"}],"trial":[{"id":"nct05546268","kind":"trial","name":"Study of Oral MRT-2359 in Selected Cancer Patients","route":"/trials/nct05546268/"},{"id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","route":"/trials/nct07745361/"}]}}